Opinion|Videos|August 30, 2024
Strategies to Manage Type 2 Inflammation in Respiratory Diseases
Author(s)Reynold A. Panettieri Jr, MD
A key opinion leader explores therapeutic approaches targeting inflammation to alleviate symptoms in COPD and asthma patients.
Advertisement
Episodes in this series
- How do these markers influence the treatment regimen for patients with asthma or COPD?
- How do comorbidities affect the management of type 2 inflammation in asthma and COPD?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
3
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
4
Early-Onset Cancers Often Found Late as Screening Gaps Persist
5